Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +114.71%
#2 Lisk Lisk +74.17%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +29.93%
#4 Tokenlon Tokenlon +28.92%
#5 Alchemist AI Alchemist AI +25.19%
#6 earnAUSD earnAUSD +24.75%
#7 Nockchain Nockchain +24.71%
#8 Renzo Renzo +22.94%
#9 ARPA ARPA +20.07%
#10 Illuvium Illuvium +18.12%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Classifica tra le azioni #96
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Prezzo delle azioni
$43.92
Ultima sincronizzazione: 2026-09-11
Capitalizzazione di mercato
$195.10B
Variazione (1 giorno)
-3.37%
Variazione (1 anno)
-17.97%
Paese
DK
Scambia Novo Nordisk A/S (NOVO-B)

Categoria

Healthcare
Rapporto P/S per Novo Nordisk A/S (NOVO-B)
Rapporto P/S al February 2026 TTM: 4.47
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Novo Nordisk A/S, il rapporto P/S attuale (TTM) è 4.47. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Novo Nordisk A/S da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
13.69 206.53%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.54 46.52%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.04 57.56%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 4.33%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
5.50 23.09%
US